Streetbeat News

Regulatory

GOSS

Gossamer Bio, Inc. (NASDAQ:GOSS) announced that data from its functional respiratory imaging (FRI) sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with pulmonary arterial hypertension (PAH) will be presented at the European Respiratory Society International Congress 2023. The presentation will be made by Dr. Roham Zamanian, Professor of Pulmonary and Critical Care Medicine at Stanford University.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:46 am

AAPL

Apple Inc.'s shares fell over 2% in premarket trading due to two developments. Firstly, Huawei launched a faster smartphone, Mate 60 Pro, which could lead to Apple losing 10 million iPhone shipments in 2024, according to an Oppenheimer analyst. Secondly, China plans to expand a ban on the use of iPhones in government offices, state companies, and government-backed agencies.

Portfolio Pulse from Shanthi Rexaline

September 07, 2023 | 11:40 am

XAIR

Beyond Air, Inc. (NASDAQ:XAIR) has announced a strategic collaboration with Getz Healthcare to commercialize the LungFit PH device in certain countries across the Asia-Pacific region, pending regulatory approvals. Beyond Air is a commercial stage medical device and biopharmaceutical company focused on improving the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:39 am

PFE

VALN

Valneva SE and Pfizer Inc have released positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15. The study showed a robust antibody response in all age groups after a booster dose. The vaccine was well-tolerated with no serious adverse events. Pfizer plans to submit a Biologics License Application to the FDA and a Marketing Authorisation Application to the European Medicines Agency in 2026, subject to positive Phase 3 data.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 11:32 am

NVO

Scientists are exploring the potential of obesity drugs to treat conditions like dementia and alcohol addiction. Novo Nordisk's Wegovy weight loss injection has shown to reduce heart failure-related symptoms among high-risk patients. The drug is being tested for its effectiveness in reducing drug and alcohol intake and reducing tau accumulation and brain inflammation in dementia patients. However, concerns about potential adverse effects, including suicidal thoughts, have been raised.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 11:27 am

BTAI

The FDA has scheduled a Type C meeting on November 8 to discuss Bioxcel Therapeutics' BXCL501 Serenity III program for the acute treatment of agitation in schizophrenia and bipolar I and II disorders in the at-home setting.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:22 am

CBAY

Cymabay Therapeutics announced that its Phase 3 RESPONSE study of Seladelpar for Primary Biliary Cholangitis has achieved the primary and all key secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:16 am

ALNY

Alnylam Pharmaceuticals has announced that its KARDIA-1 Phase 2 study of Zilebesiran has met its primary endpoint. This suggests that the drug is effective and safe for its intended use.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:11 am

DRRX

DURECT Corporation has announced the last patient's last visit in the Phase 2b AHFIRM trial of Larsucosterol for Alcohol-Associated Hepatitis. This marks a significant milestone in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 11:09 am

TSLA

Mozilla Foundation has criticized the privacy policies of modern cars, including Tesla Inc. (NASDAQ:TSLA), stating that they are a 'privacy nightmare'. The foundation found that all 25 car brands it researched, including Tesla, Audi, Mercedes-Benz, Kia, Lexus, and Toyota, were collecting 'too much' personal data, often for purposes beyond operating the vehicle. Tesla's privacy policy was rated the worst among the 25 car makers reviewed.

Portfolio Pulse from Rounak Jain

September 07, 2023 | 10:57 am